Eversept Partners LP increased its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 54.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 657,834 shares of the company’s stock after acquiring an additional 231,335 shares during the quarter. Abivax comprises 4.5% of Eversept Partners LP’s holdings, making the stock its 4th largest position. Eversept Partners LP’s holdings in Abivax were worth $88,712,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. WPG Advisers LLC grew its stake in shares of Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in shares of Abivax during the fourth quarter worth $61,000. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Abivax during the fourth quarter worth $67,000. Institutional investors and hedge funds own 47.91% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts recently commented on ABVX shares. Morgan Stanley lowered their target price on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, June 2nd. Truist Financial decreased their price objective on shares of Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. Barclays upped their price objective on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Wedbush upgraded shares of Abivax from an “underperform” rating to a “neutral” rating and decreased their price objective for the company from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Finally, Citigroup restated an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $130.08.
Abivax Price Performance
NASDAQ ABVX opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a 1 year low of $5.69 and a 1 year high of $148.83. The company has a market capitalization of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69. The company has a fifty day moving average of $114.81 and a two-hundred day moving average of $118.49.
Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, research analysts expect that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.
Abivax Company Profile
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Read More
- Five stocks we like better than Abivax
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
